Clinical Trials in Chicago

Showing 4041-4060 of 20,493 trials

Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML)

NCT05744739

Phase 1 of the study will open first with a (Bayesian optimal interval BOIN) dose finding design. The starting dose of tomivosertib is 100mgdaily (doses 24 ± 2 hours apart), PO, self-administered with meals. The dose finding follows a BOIN design, with the 100mg BID dose level with a meal being the highest dose. There is one dose level below (dose level -1 = 100mg QD without a meal) that will be given if the de-escalation condition is met during dose finding. Upon completion of the phase 1 dose finding portion of the study, the recommended starting dose of tomivosertib for the subsequent combination with the other agents will be determined, as described in Section 4.3 and Section 8.0. Tomivosertib will be dosed continuously on days 1-28 of each 28-day cycle at the dose level assigned for that cohort.

Acute Myeloid Leukemia

Northwestern University15 participantsStarted Sep 2023

Chicago, Illinois, United States

COMPLETEDPhase 22.2 miles

Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder (CURB-2)

NCT05262270

This is an 8-week, double-blind, randomized placebo-controlled trial of the efficacy of a combination of extended-release naltrexone (XR-NTX) and extended-release buprenorphine (XR-BUP) compared to matched placebo injections (PBO-Inj) for the treatment of cocaine use disorder (CUD).

Cocaine Use Disorder

University of Texas Southwestern Medical Center427 participantsStarted Apr 2023

Birmingham, Alabama, United States • Little Rock, Arkansas, United States • Los Angeles, California, United States +9 more locations

Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML)

Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder (CURB-2)

Find Trials by Condition in Chicago

Nonhealing Diabetic Foot Ulcers Treated With Standard of Care (SOC) Alone or Standard of Care and Amnion-Intermediate-Chorion (AIC)

A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease

A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes

Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)

GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer

GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease

Medtronic Transcatheter Aortic Valve Replacement (TAVR) Low Risk Bicuspid Study

Study of Daxdilimab (HZN-7734) in Participants With Moderate-to-Severe Primary Discoid Lupus Erythematosus

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients

A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants

A Study of ZW171 in Participants With Advanced or Metastatic Mesothelin-expressing Cancers

A Study to Evaluate Early Treatment Outcomes With Miebo™ in Subjects With Dry Eye Disease

First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)

Artacent Amniotic Tissue for Treatment of Chronic Lower Extremity Diabetic Ulcers.

Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection

Hearing Impairment, Strategies and Outcomes in VA Emergency Departments